Capacity – Talk Bio

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

23 hours ago talkbio0Tagged Biological Factors, Boost, Capacity, CDMO, Fujifilm, Manufacture, Regeneron, United States

Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

1 month ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany

3 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Cancer Research, Capacity, Daiichi, Germany, innovation, Manufacturing, Pfaffenhofen facility, Sankyo

Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center

Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years

10 months ago talkbio0Tagged Capacity, development aspects, Drug Industry, Investments, Italy, Johnson and Johnson, Manufacture, research, Upgrade

Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry

Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity

12 months ago talkbio0Tagged Capacity, Drug Industry, drug manufacturing, Eli Lilly, financial outlook, Mounjaro, production, Zepbound

Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.

Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma

12 months ago talkbio0Tagged Acquisition (action), Capacity, Eli Lilly, expansion, Facility (object), Injectables, Nexus Pharma, pharmaceutical manufacturing, production, strategic

Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

12 months ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

1 year ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

Lonza Acquires Roche’s Massive Biologics Production Facility in Vacaville, California for $1.2 Billion

1 year ago talkbio0Tagged Biologics Manufacturing Site, California, Capacity, CDMOs, Contract Development, genentech, Global Biologics Market, Growth, Large-Scale Commercial Mammalian Products, Lonza, manufacturing organizations, Roche (company), utilization qualifier, Vacaville

Lonza, Roche, Genentech, Biologics Manufacturing Site, Vacaville/ California, $1.2 Billion Deal, Large-Scale Commercial Mammalian Products, Expansion Plans ($561 Million), Capacity Utilization, Contract Development and Manufacturing Organizations (CDMOs), Global Biologics Market Growth